KYMR Stock Overview
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Kymera Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$37.40 |
| 52 Week High | US$45.31 |
| 52 Week Low | US$9.60 |
| Beta | 2.27 |
| 1 Month Change | 0.73% |
| 3 Month Change | 13.44% |
| 1 Year Change | 28.92% |
| 3 Year Change | -15.10% |
| 5 Year Change | n/a |
| Change since IPO | 12.45% |
Recent News & Updates
Recent updates
We Think Kymera Therapeutics (NASDAQ:KYMR) Can Easily Afford To Drive Business Growth
May 03
Kymera Therapeutics: Advancing Into Phase 2 With Partner Sanofi - I Still Have Faith
Mar 21Kymera Therapeutics, Inc. (NASDAQ:KYMR) Released Earnings Last Week And Analysts Lifted Their Price Target To US$47.43
Feb 25Optimistic Investors Push Kymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Up 39% But Growth Is Lacking
Feb 17Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Shares Climb 33% But Its Business Is Yet to Catch Up
Dec 29We Think Kymera Therapeutics (NASDAQ:KYMR) Needs To Drive Business Growth Carefully
Nov 06Industry Analysts Just Made A Substantial Upgrade To Their Kymera Therapeutics, Inc. (NASDAQ:KYMR) Revenue Forecasts
Aug 31Here's Why We're Not Too Worried About Kymera Therapeutics' (NASDAQ:KYMR) Cash Burn Situation
Aug 04Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Share Price Not Quite Adding Up
May 21We're Hopeful That Kymera Therapeutics (NASDAQ:KYMR) Will Use Its Cash Wisely
Apr 16Companies Like Kymera Therapeutics (NASDAQ:KYMR) Are In A Position To Invest In Growth
Dec 28Kymera KT-333 gets FDA orphan drug status for blood cancer subtype
Sep 15Kymera initiated at buy at Jefferies on promise in oncology, autoimmune spaces
Aug 15Kymera Therapeutics GAAP EPS of -$0.78 misses by $0.08, revenue of $11.51M misses by $3.46M
Aug 09Here's Why We're Not Too Worried About Kymera Therapeutics' (NASDAQ:KYMR) Cash Burn Situation
Jul 04Kymera Therapeutics: A First Take
Feb 28Companies Like Kymera Therapeutics (NASDAQ:KYMR) Can Afford To Invest In Growth
Feb 28Shareholder Returns
| KYMR | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 12.1% | 4.7% | 0.7% |
| 1Y | 28.9% | 2.7% | 23.9% |
Return vs Industry: KYMR exceeded the US Biotechs industry which returned 2.9% over the past year.
Return vs Market: KYMR exceeded the US Market which returned 24.2% over the past year.
Price Volatility
| KYMR volatility | |
|---|---|
| KYMR Average Weekly Movement | 7.1% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: KYMR has not had significant price volatility in the past 3 months.
Volatility Over Time: KYMR's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 187 | Nello Mainolfi | www.kymeratx.com |
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus.
Kymera Therapeutics, Inc. Fundamentals Summary
| KYMR fundamental statistics | |
|---|---|
| Market cap | US$2.23b |
| Earnings (TTM) | -US$154.59m |
| Revenue (TTM) | US$79.41m |
28.9x
P/S Ratio-14.8x
P/E RatioIs KYMR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KYMR income statement (TTM) | |
|---|---|
| Revenue | US$79.41m |
| Cost of Revenue | US$189.08m |
| Gross Profit | -US$109.67m |
| Other Expenses | US$44.92m |
| Earnings | -US$154.59m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.52 |
| Gross Margin | -138.10% |
| Net Profit Margin | -194.67% |
| Debt/Equity Ratio | 0% |
How did KYMR perform over the long term?
See historical performance and comparison